Preview Mode Links will not work in preview mode

Jul 14, 2020

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Interview with Dr Coleman on the following topics:

  • Clinical implications of the Phase III VELIA study assessing veliparib in combination with carboplatin/paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC (00:00)
  • Homologous recombination deficiency testing and implications for treatment decision-making in newly diagnosed advanced OC (4:11)
  • Risks with combining PARP inhibitor therapy and chemotherapy for advanced OC; optimizing the use of chemotherapy, bevacizumab and a PARP inhibitor in the front-line setting (7:19)

CME information and select publications